PRAXIS PRECISION MEDICINES INC
NASDAQ: PRAX (Praxis Precision Medicines, Inc)
Last update: 18 hours ago189.99
27.28 (16.77%)
| Previous Close | 162.71 |
| Open | 178.94 |
| Volume | 4,422,289 |
| Avg. Volume (3M) | 735,656 |
| Market Cap | 4,021,315,584 |
| Price / Sales | 144.69 |
| Price / Book | 2.87 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Operating Margin (TTM) | -2,868.84% |
| Diluted EPS (TTM) | -10.66 |
| Quarterly Revenue Growth (YOY) | 1,349.10% |
| Total Debt/Equity (MRQ) | 0.24% |
| Current Ratio (MRQ) | 8.44 |
| Operating Cash Flow (TTM) | -163.91 M |
| Levered Free Cash Flow (TTM) | -90.04 M |
| Return on Assets (TTM) | -39.95% |
| Return on Equity (TTM) | -63.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Praxis Precision Medicines, Inc | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.75 |
|
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.16% |
| % Held by Institutions | 122.02% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Adage Capital Partners Gp, L.L.C. | 30 Jun 2025 | 1,974,585 |
| Cormorant Asset Management, Lp | 30 Jun 2025 | 1,625,000 |
| Soleus Capital Management, L.P. | 30 Jun 2025 | 966,740 |
| Point72 Asset Management, L.P. | 30 Jun 2025 | 954,075 |
| Perceptive Advisors Llc | 30 Jun 2025 | 752,921 |
| Baker Bros. Advisors Lp | 30 Jun 2025 | 689,488 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 360.00 (Truist Securities, 89.48%) | Buy |
| Median | 290.00 (52.64%) | |
| Low | 83.00 (Jones Trading, -56.31%) | Buy |
| Average | 273.13 (43.76%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 161.67 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 17 Oct 2025 | 330.00 (73.69%) | Buy | 189.99 |
| 29 Jul 2025 | 80.00 (-57.89%) | Buy | 55.96 | |
| Deutsche Bank | 17 Oct 2025 | 280.00 (47.38%) | Buy | 189.99 |
| Guggenheim | 17 Oct 2025 | 350.00 (84.22%) | Buy | 189.99 |
| Truist Securities | 17 Oct 2025 | 360.00 (89.48%) | Buy | 189.99 |
| HC Wainwright & Co. | 16 Oct 2025 | 232.00 (22.11%) | Buy | 162.71 |
| 05 Aug 2025 | 115.00 (-39.47%) | Buy | 47.79 | |
| Jefferies | 16 Oct 2025 | 300.00 (57.90%) | Buy | 162.71 |
| Needham | 16 Oct 2025 | 250.00 (31.59%) | Buy | 162.71 |
| Jones Trading | 18 Sep 2025 | 83.00 (-56.31%) | Buy | 45.23 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |